Understanding microvascular inflammation in kidney transplants
Official title: Comprehensive Multiscale Characterization of the Molecular Landscape of Microvascular Inflammation in Kidney Allografts
Run by Paris Translational Research Center for Organ Transplantation · NCT06342128 · Data updated 2026-11-12
This study looks at how inflammation in small blood vessels affects kidney transplants to see if understanding it better can help improve treatment for kidney transplant patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Paris Translational Research Center for Organ Transplantation Academic / other |
| Locations | 3 sites (Paris and 2 other locations) |
| Status | Recruiting |
| Started | January 1, 2022 |
| Main results expected | June 1, 2024 |
| Study ends | December 2025 |
| Registry record updated | May 31, 2025 |
| Trial ID | NCT06342128 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult kidney transplant recipients who have undergone at least one biopsy assessed according to the Banff 2022 classification.
✕Probably not a fit
Patients with inadequate biopsy samples or those showing signs of ischemia-reperfusion may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the molecular landscape of microvascular inflammation in kidney allografts, particularly in light of recent updates to the Banff classification. By employing a multimodal phenotyping approach, including histological analyses and transcriptomic profiling, the study seeks to identify the pathophysiological mechanisms associated with different phenotypes of microvascular inflammation. The findings will be compared across various clinical scenarios to enhance understanding and potentially guide targeted therapeutic strategies for kidney transplant recipients.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for kidney transplant recipients experiencing microvascular inflammation.
How similar studies have gone: While the study addresses a critical area of kidney transplant research, the specific approach of deciphering the molecular landscape of microvascular inflammation is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Adult kidney transplant recipients, with at least one kidney transplant biopsy performed and assessed according to the international Banff 2022 classification, with or without lesions of microvascular inflammation Exclusion Criteria: * Inadequate biopsy according to the Banff classification * Missing data for Banff lesion scores, donor-specific antibody status, C4d staining * Biopsies showing histological signs of ischemia-reperfusion * Combined transplantation and kidney transplantation after a non-kidney solid organ transplantation
Where it's running
-
Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France Recruiting -
Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France Recruiting -
Bichat Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France Recruiting
Study contacts
- Study coordinator: Alexandre Loupy, MD PhD
- Email: alexandreloupy@inserm.fr
- Phone: +33612491082
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How kidney transplant patients feel about using artificial intelligence in medicine
This international survey asks adults who have had a kidney transplant how they feel about AI tools that predict graft loss and what it might mean for their daily care.
-
Personalized therapeutic stories for children after kidney transplant.
We will test whether clinician-supervised AI can create age-appropriate, personalized therapeutic stories for children aged 5–12 who have received a kidney transplant and their families.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.